Entresto starts working in your body within hours of the first dose, but the benefits that matter most for heart failure, like stronger heart function and fewer hospitalizations, build gradually over weeks to months. The drug reaches peak levels in your bloodstream within about 30 minutes to 2 hours, depending on the component. Meaningful improvements in heart failure markers typically appear by 4 weeks, with deeper benefits continuing to accumulate for a year or more.
What Happens in the First Hours
Entresto contains two active components that work on different timelines. One (sacubitril) reaches peak concentration in your blood within about 30 minutes, then gets converted into its active form, which peaks at around 2 hours. The other (valsartan) peaks at about 1.5 hours. So within the first couple of hours after your first dose, both components are fully active in your system.
This means blood pressure can start dropping within the first day or two. Some people notice dizziness or lightheadedness early on, which is actually a sign the medication is doing its job. This effect often settles as your body adjusts, especially during the titration period.
The Titration Period: First 2 to 8 Weeks
Most people don’t start on the full dose of Entresto. Your doctor will typically begin with a lower dose and double it every 2 to 4 weeks until you reach the target maintenance dose. This gradual ramp-up helps your body adjust and reduces side effects like low blood pressure or dizziness.
If you’re switching from an ACE inhibitor, there’s a mandatory 36-hour gap between stopping the old medication and starting Entresto. This washout period prevents a serious allergic reaction called angioedema. If you’re switching from another type of blood pressure medication (an ARB), no waiting period is needed.
Measurable Improvements by 4 Weeks
One of the clearest early signs that Entresto is working comes from a blood test measuring NT-proBNP, a protein your heart releases when it’s under strain. Higher levels mean your heart is working harder than it should. By week 4, Entresto reduces this marker by about 27% compared to older heart failure medications. You won’t feel this change directly, but it signals that the stress on your heart is already easing.
That reduction keeps deepening: by 12 weeks, NT-proBNP levels drop by roughly 50%, and by one year, they’re down about 65% from where they started. Your doctor may order periodic blood tests to track this progress, which is one of the most reliable ways to confirm the drug is working for you specifically.
Heart Function Improves Over Months
The change most people care about is whether their heart actually gets stronger, measured by ejection fraction (the percentage of blood your heart pumps out with each beat). This type of improvement, called reverse remodeling, takes considerably longer than the early biomarker changes.
Research tracking patients on Entresto found that ejection fraction improved meaningfully over 12 months of treatment. People who had been diagnosed with heart failure for less than a year saw the largest gains, with an average improvement of about 12 percentage points. Those with longer-standing heart failure still benefited, gaining roughly 7 to 9 percentage points on average. To put that in perspective, a normal ejection fraction is 55% or higher, and many heart failure patients start in the 20% to 35% range, so a jump of 7 to 12 points is significant.
Along with ejection fraction, the physical size of the heart chambers also tends to shrink during this period. An enlarged heart is a hallmark of heart failure, and this structural reversal is one of the most meaningful signs that the disease trajectory is changing.
Long-Term Benefits Over 1 to 2 Years
The landmark trial that led to Entresto’s approval followed patients for a median of 27 months. Over that period, Entresto reduced the combined risk of heart failure hospitalizations and cardiovascular death by 20% to 24% compared to the older standard treatment. That reduction applied to both first-time hospitalizations and repeat events, meaning the protective effect didn’t wear off over time.
Many people with heart failure measure progress by how they feel day to day: less shortness of breath, more energy, better exercise tolerance, fewer episodes of fluid retention. These symptom improvements tend to emerge gradually during the first few months, often becoming noticeable around the same time that biomarker levels are dropping. But because heart failure symptoms fluctuate naturally, it can be hard to pinpoint exactly when things start feeling better. The blood tests offer a more objective picture.
Why It Feels Like a Slow Process
Entresto works through two distinct mechanisms simultaneously. One part blocks a hormone that constricts blood vessels and promotes fluid retention, reducing the immediate workload on your heart. The other part boosts natural peptides that help blood vessels relax and encourage your kidneys to shed excess salt and water. The first mechanism produces relatively fast effects on blood pressure and fluid balance. The second drives the slower, deeper remodeling of heart tissue.
This is why the full picture of “how long it takes to work” spans such a wide range. Blood pressure changes happen in days. Stress markers improve in weeks. Heart structure remodels over months. And the reduction in hospitalizations and deaths plays out over a year or two. Each of these timelines represents a real, measurable layer of benefit, and they stack on top of each other as treatment continues.
If you’ve been on Entresto for a few weeks and don’t feel dramatically different, that’s normal. The most important changes are happening at a level you can’t directly sense, and they take time to translate into how you feel and how well your heart functions on imaging.